ClinicaliQ Trial Snapshot
- A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA) — Recruiting • Phase III • Rheumatology • NCT04088396.
- Trial testing whether baricitinib is safe and effective for treating systemic juvenile idiopathic arthritis in children aged 1-18 years.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The reason for this study is to see if the study drug baricitinib is safe and effective in participants from 1 year to less than 18 years old with systemic juvenile idiopathic arthritis (sJIA). Participants are assigned to 1 of 2 cohorts. In cohort 1, participants will receive baricitinib or tocilizumab reference. In cohort 2, participants will receive baricitinib. Conditions: Systemic Juvenile Idiopathic Arthritis Interventions: Baricitinib, Tocilizumab Lead Sponsor: Eli Lilly and Company Planned Enrollment: 58 participants